Welcome to our dedicated page for Hemab Therapeutics Holdings news (Ticker: COAG), a resource for investors and traders seeking the latest updates and insights on Hemab Therapeutics Holdings stock.
Hemab Therapeutics Holdings reports corporate and clinical-stage biotechnology developments tied to its blood coagulation disorder programs. Company news includes its Nasdaq listing and initial public offering, capital-structure updates, shareholder voting matters, and clinical or regulatory disclosures related to rare bleeding disorder therapeutics.
Updates for COAG also center on Hemab's development focus, including sutacimig (HMB-001), a bispecific antibody program for prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.
Hemab Therapeutics (Nasdaq: COAG) priced an upsized initial public offering of 16,750,000 shares at $18.00 per share, with a 30-day underwriter option for an additional 2,512,500 shares.
Gross proceeds are expected to be approximately $301.5 million before underwriting discounts, and trading on the Nasdaq Global Select Market is expected to begin on May 1, 2026 with closing on or about May 4, 2026.